Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | BCR | P11274 | 2/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.40 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.40 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.40 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.40 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847594 | 0.78 | RAB9A (0.61) | ALDH1A3ABL1ABCB1BCRNPC1 | |
| SCHEMBL7172987 | 0.78 | ALDH1A3 (0.42) | ALDH1A3CYP1A2CYP2A6CYP11B1CYP11B2 | |
| SCHEMBL3889948 | 0.77 | HRH3 (0.47) | ALDH1A3CYP1A2NPC1RAB9AKDM4E | |
| SCHEMBL7167040 | 0.74 | ACHE (0.43) | ALDH1A3ABL1ABCB1BCRCYP1A1 | |
| SCHEMBL7994448 | 0.73 | MMP3 (0.46) | ABL1ABCB1BCRCYP3A4CYP2C9 | |
| SCHEMBL1645629 | 0.73 | ALDH1A3 (0.42) | ALDH1A3CYP11B1CYP11B2NPC1RAB9A | |
| SCHEMBL7169837 | 0.72 | TP53 (0.39) | CYP1A2CYP2A6NPC1RAB9AKDM4E | |
| SCHEMBL1851663 | 0.72 | NPC1 (0.58) | ALDH1A3ABL1ABCB1BCRCYP1A1 | |
| SCHEMBL2407878 | 0.71 | CYP1A1 (0.74) | ABL1ABCB1BCRCYP1A1CYP1A2 | |
| SCHEMBL6821430 | 0.70 | PDE10A (0.46) | ALDH1A3ADORA1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486962-B2 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | F2G LTD. (GB) | 2013-07-16 | — | — | US | disclosed |
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LTD (GB) | 2011-07-28 | — | — | US | disclosed |
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LTD (GB) | 2011-07-28 | — | — | US | disclosed |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD. | 2010-03-04 | — | — | US | disclosed |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD. | 2010-03-04 | — | — | US | disclosed |
| WO-2009144473-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LIMITED (GB) | 2009-12-03 | — | — | WO | disclosed |
| EP-1888063-B1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20080161302-A1 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | F2G LTD. (GB) | 2008-07-03 | — | — | US | disclosed |
| EP-1888063-A1 | ANTIFUNGAL AGENTS | F2G Ltd. (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006123145-A1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161302-A1 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | NAT1, CYP1A2, CYP51A1 | ALDH1A3 2640/4885ABL1 564/4885ABCB1 1740/4885 |
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | IDO1, FOXM1, IPO5 | ALDH1A3 3749/4885ABL1 814/4885ABCB1 106/4885 |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | NAT1, AGXT, CYP1A2 | ALDH1A3 1576/4885ABL1 803/4885ABCB1 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.